UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Enhance Wellness for Individuals With Long-Term Physical Disabilities

Not Applicable

Completed

Conditions: Multiple Sclerosis
Muscular Dystrophy
Spinal Cord Injury
Post-polio Syndrome

Interventions: Behavioral: Enhance Wellness

First Posted Date: 2016-06-28

Last Posted Date: 2018-04-03

Lead Sponsor: University of Washington

Target Recruit Count: 240

Registration Number: NCT02815878

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Stroke and CPAP Outcome Study 2

Not Applicable

Completed

Conditions: Stroke
Sleep Apnea, Obstructive
Patient Adherence

Interventions: Device: Continuous Positive Airway Pressure

First Posted Date: 2016-06-22

Last Posted Date: 2020-12-23

Lead Sponsor: University of Washington

Target Recruit Count: 90

Registration Number: NCT02809430

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Brief Restructuring Intervention Following Trauma Exposure

Not Applicable

Completed

Conditions: Posttraumatic Stress Disorder
Alcohol Use Disorders

Interventions: Behavioral: Brief Cognitive Therapy

First Posted Date: 2016-06-21

Last Posted Date: 2025-02-26

Lead Sponsor: University of Washington

Target Recruit Count: 57

Registration Number: NCT02808468

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Collaborative Care From the ED for Trauma Patients With Prescription Drug Misuse

Not Applicable

Completed

Conditions: Substance-Related Disorders

Interventions: Other: Collaborative Care Intervention

First Posted Date: 2016-06-17

Last Posted Date: 2016-06-17

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT02804295

The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial

Not Applicable

Completed

Conditions: Appendicitis

Interventions: Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin
Procedure: Appendectomy

First Posted Date: 2016-06-15

Last Posted Date: 2023-05-06

Lead Sponsor: University of Washington

Target Recruit Count: 1552

Registration Number: NCT02800785

Locations: 🇺🇸
Maine Medical Center, Portland, Maine, United States
🇺🇸
Olive View-UCLA Medical Center, Sylmar, California, United States
🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

and more 22 locations

Mexiletine in Sporadic Amyotrophic Lateral Sclerosis

Phase 2

Completed

Conditions: Sporadic Amyotrophic Lateral Sclerosis

Interventions: Drug: Placebo
Drug: Mexiletine

First Posted Date: 2016-05-24

Last Posted Date: 2019-12-05

Lead Sponsor: University of Washington

Target Recruit Count: 20

Registration Number: NCT02781454

Locations: 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸
University of Washington, Seattle, Washington, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 7 locations

Evaluation of an mHealth SMS Dialogue Strategy to Meet Women's and Couples' Postpartum Contraceptive Needs in Kenya

Not Applicable

Completed

Conditions: Postpartum Period
Contraception

Interventions: Behavioral: Two-way SMS

First Posted Date: 2016-05-24

Last Posted Date: 2018-05-03

Lead Sponsor: University of Washington

Target Recruit Count: 260

Registration Number: NCT02781714

Locations: 🇰🇪
Bondo County Hospital, Bondo, Siaya County, Kenya
🇰🇪
Ahero sub-County Hospital, Ahero, Kisumu County, Kenya

Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission

Phase 1

Active, not recruiting

Conditions: No Evidence of Disease
HER2/Neu Negative
Stage IB Breast Cancer
Stage III Breast Cancer
Stage IIIA Breast Cancer
Stage IIA Breast Cancer
Stage II Breast Cancer
Stage IIIB Breast Cancer
One or More Positive Axillary Nodes
Stage IIIC Breast Cancer

Interventions: Other: Laboratory Biomarker Analysis
Biological: pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
Biological: Sargramostim

First Posted Date: 2016-05-23

Last Posted Date: 2022-01-13

Lead Sponsor: University of Washington

Target Recruit Count: 24

Registration Number: NCT02780401

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

PrEP in Breastfeeding Study

Phase 2

Completed

Conditions: HIV Pre-exposure Prophylaxis During Breastfeeding

Interventions: Drug: FTC/TDF PrEP

First Posted Date: 2016-05-18

Last Posted Date: 2021-09-21

Lead Sponsor: University of Washington

Target Recruit Count: 50

Registration Number: NCT02776748

Locations: 🇺🇬
Partners in Prevention-Infectious Diseases Institute LTD, Kampala, Uganda
🇰🇪
Partners in Prevention-Thika, Thika, Kenya

Partners Demonstration Project of PrEP and ART

Phase 4

Completed

Conditions: HIV Infection

Interventions: Drug: FTC-TDF PrEP
Drug: ART

First Posted Date: 2016-05-18

Last Posted Date: 2017-12-08

Lead Sponsor: University of Washington

Target Recruit Count: 1013

Registration Number: NCT02775929

Locations: 🇺🇬
Kabwohe Clinical Research Center, Bushenyi, Uganda
🇰🇪
Partners in Prevention-Thika, Thika, Kenya
🇺🇬
Partners in Prevention-Infectious Diseases Institute LTD, Kampala, Uganda

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy